VANCOUVER, BC, July 26,
2024 /CNW/ --
PLEASE READ CAREFULLY. IGNORING THIS NOTICE
WILL AFFECT YOUR LEGAL RIGHTS.
K.S. Garcha of Dusevic & Garcha announces
that a Canada-wide settlement
("Settlement") (excluding residents of Quebec) has been reached with respect to
Janssen Inc., Janssen Pharmaceuticals, Inc., and Janssen Research
& Development, LLC (the "Janssen Defendants") and Bayer Inc. in
a proposed class action relating to the
fluoroquinolone prescription drugs Levaquin, Cipro
and Avelox and Peripheral Neuropathy. "Levaquin" means
Levaquin® branded (i.e., not generic) levofloxacin
tablets and/or intravenous solution distributed in Canada by
the Janssen Defendants. "Cipro" means all formulations of
Cipro® branded (i.e., not generic) ciprofloxacin
distributed or licensed in Canada
by Bayer Inc. "Avelox"
means all formulations of Avelox® branded
(i.e., not generic)
moxifloxacin distributed or licensed in Canada
by Bayer Inc.
As a part of the settlement process, the following lawsuit (the
"Proceeding") has been certified against the Janssen Defendants and
Bayer Inc. as a class action for settlement
purposes: Lloyd Achtymichuk v. Bayer Inc.,
Janssen Inc., Janssen Pharmaceuticals, Inc., and Janssen Research
& Development, LLC, in the Vancouver Registry
of the Supreme Court of British Columbia under Court
File No. S167919.
A hearing to approve the Settlement has been scheduled for
November 1, 2024 at 10:00 a.m. Pacific Time in the Supreme
Court of British Columbia.
If the Settlement is approved, it will apply to: (i) All persons
resident in Canada (excluding
residents of Quebec) who were
prescribed and/or ingested Levaquin, Cipro or Avelox in
Canada at any time on or
before the date of the certification
order; and (ii) All persons
who by virtue of a personal relationship
to one or more of such persons described in (i) above
have claims for common law or statutory damages (the "Class").
To determine whether you may be eligible to receive
compensation, visit www.garchaandcompany.ca.
If you qualify as a member of the Class and wish to
participate in the Settlement, you do not need to do anything at
this time. If the Settlement is approved by the
Court mentioned above, another notice will be published, and
additional information will be provided on how to make
a claim.
If you qualify as a Class Member and you do not wish to
participate in the Settlement, then you must opt out by completing
an Opt Out Form and submitting it to Class Counsel. Class Members
who do not opt out will be bound by the Settlement and the releases
in it, if it is approved, and will be entitled to share in any of
the benefits that may become available to them as Class Members,
provided that they proceed within the timeframes provided to
advance their claims. The deadline to opt out of the Settlement
and the Proceeding is September 24, 2024.
If you wish to remain a Class
Member but object to the Settlement,
you must submit a written objection no later
than 5:00 p.m. Pacific Time,
October 27, 2024.
CONTACT
This is an abbreviated notice. For the complete notice,
including information on benefits that may be
available through the Settlement, copies
of the Settlement Agreements,
how to participate in the Settlement Approval
Hearing, the Opt Out Form, information on how to object to the
approval of the Settlement Agreements, and all other related
information is available at www.garchaandcompany.ca, or by
contacting:
DUSEVIC & GARCHA
Barristers & Solicitors
#210 - 4603 Kingsway
Burnaby, BC V5H 4M4
Tel: 604-436-3315 or 1-844-878-0444 (toll free)
Fax: 604-436-3302
Email: ksgarcha@dusevicgarchalaw.ca
Please do not call the Defendants or the Court
about the Proceeding.
This Notice has been approved by the Supreme Court of
British Columbia.
SOURCE DUSEVIC & GARCHA
SOURCE DUSEVIC & GARCHA